Oramed Pharmaceuticals moves forward with NDA for oral insulin


Oramed Pharmaceuticals announced that it has been in communication with the FDA regarding its Investigational New Drug application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.

View Comments (0)